D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Following the agreement, Vanda is preparing BLA and MAA applications for the US and EU, with a focus on commercialization. Imsidolimab, a fully humanized IgG4 antibody, is expected to provide ...

Ugandan doctors attend the contacts of a patient who had tested positive, during the launch of the vaccination for the Sudan strain of Ebola virus, with a trial vaccine at the Mulago Guest House ...

It later moved into medicines, commercialising aspirin around the turn of the 20th century, one of the most successful pharmaceuticals ever at that point. The unregulated nature of the trade in ...